These findings provide novel evidence for the anti-metastatic and anti-angiogenic properties of angelol-a in human cervical cancer cells through modulation of the ERK pathway and targeting the miR-29a-3p/MMP2/VEGFA axis. The gene discussed is VEGFA; the disease is cervical carcinoma.